2023年11月17日，制药公司赛诺菲（Sanofi）宣布， Dupilumab（通用名：度普利尤单抗）在中国获批用于12岁及以上青少年和成人哮喘患者的维持治疗。 度 ...

法国里尔天主教医院团队在《Journal Fran?ais d'Ophtalmologie》发表的前瞻性观察研究OASIS，创新性地采用眼科-皮肤科联合评估模式。研究纳入2018-2019年间46例中重度AD患者，通过标准化眼科检查方案（包括OSDI评分、Schirmer试验、泪膜破裂时间测定及裂隙灯检查），结合SCORAD、EASI等皮肤评分系统，对Dupilumab ...

Dupilumab治疗COPD的2型炎症生物标志物分析：BOREAS III期试验的预测价值与动态变化 《The Lancet Respiratory Medicine》：Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a ...

Dupilumab（度普利尤单抗），一种结合IL-4Rα并抑制IL-4和IL-13信号传导的全人源单克隆抗体，一经获批上市即在特应性皮炎和哮喘等疾病领域“大展身手 ...

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

日前，Regeneron Pharmaceuticals和赛诺菲（Sanofi）公司宣布，两公司联合开发的重磅药物Dupixent（dupilumab），在治疗鼻息肉慢性鼻窦炎（CRSwNP）成人患者的 ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.“The ...